Öppna denna publikation i ny flik eller fönster >>Department of Radiology, Rigshospitalet, Oslo University Hospital, Oslo, Norway.
Department of Surgical Gastroenterology and Transplantation, Rigshospitalet, University of Copenhagen, Denmark.
Department of Surgical Gastroenterology and Transplantation, Rigshospitalet, University of Copenhagen, Denmark.
Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.
Department of Radiology, Rigshospitalet, Oslo University Hospital, Oslo, Norway.
Department of Surgery, Skåne University Hospital, Lund.
Department of Surgery, Skåne University Hospital, Lund.
Linköpings universitet, Institutionen för biomedicinska och kliniska vetenskaper, Avdelningen för kirurgi, ortopedi och onkologi. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Kirurgiska kliniken US.
Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Asklepios Hospital Barmbek, Hamburg, Germany.
Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm.
Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm.
Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm.
Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Asklepios Hospital Barmbek, Hamburg, Germany.
Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm.
Linköpings universitet, Institutionen för biomedicinska och kliniska vetenskaper, Avdelningen för kirurgi, ortopedi och onkologi. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Kirurgiska kliniken US.
Visa övriga...
2025 (Engelska)Ingår i: HPB, ISSN 1365-182X, E-ISSN 1477-2574Artikel i tidskrift (Refereegranskat) Epub ahead of print
Abstract [en]
Background: Portal vein embolization (PVE) is a well-established technique for inducing liver hypertrophy in the future liver remnant (FLR) before major hepatectomy. A frequently used method in bilobar disease is the two-stage hepatectomy (TSH) technique combined with PVE (TSH-PVE). A novel approach is PVE, followed by a one-stage hepatectomy (OSH), combining major hepatectomy with clearing of the FLR (PVE-OSH). This study aimed to compare FLR hypertrophy between these two strategies for induced liver hypertrophy.
Material/methods: Patients with bilobar colorectal liver metastases (CRLM) who underwent PVE from January 2013 to December 2021 were included in this retrospective, multicenter study. Aspects of hypertrophy of the FLR were compared between the groups.
Results: The study included 188 patients, 127 in the PVE-OSH group and 61 in the TSH-PVE group. There were no statistically significant differences between the two groups regarding FLR hypertrophy measured by absolute and relative growth, degree of hypertrophy or kinetic growth rate. No major complications were reported.
Discussion/conclusion: No differences in FLR hypertrophy were demonstrated between the two different treatment strategies of TSH-PVE or PVE-OSH. This supports PVE-OSH as a feasible treatment option that reduces the surgical burden for patients with advanced, bilobar CRLM disease.
Ort, förlag, år, upplaga, sidor
Elsevier BV, 2025
Nationell ämneskategori
Gastroenterologi och hepatologi
Identifikatorer
urn:nbn:se:liu:diva-220613 (URN)10.1016/j.hpb.2025.12.006 (DOI)41419351 (PubMedID)2-s2.0-105025530636 (Scopus ID)
2026-01-162026-01-162026-01-21Bibliografiskt granskad